When Does Imbruvica Patent Expire?

Imbruvica still has substantial patent life remaining. The earliest expiration is 2032 — 5.7 years out — and the full portfolio runs to 2042. That is comfortably outside the standard window for ANDA filings, but pre-approved biosimilar developers often begin clinical equivalence work 6 to 8 years before composition expiry.

Because Imbruvica's earliest patent expiry is more than three years out, generic competition is not imminent. ANDA filings can occur as early as four years after NDA approval (the so-called "5-year exclusivity wall"), but actual market entry is gated by the latest unexpired patent. For clinicians and payers, the planning horizon for generic substitution on Imbruvica is 2032 at the earliest.

For the authoritative listing of patents tied to a specific drug — the patents an ANDA filer is legally required to address under 21 USC § 355(j) — consult the FDA Orange Book. Underlying utility patent data on this page is sourced from USPTO PatentsView, the federal government's free public patent API.

Imbruvica is protected by 5 US patents, a mid-sized portfolio that is typical for an established branded drug in mid-lifecycle. The portfolio likely combines a primary composition-of-matter patent (the strongest form of protection) with a layer of formulation, dosing, and method-of-use patents that extend exclusivity beyond the original composition expiry — a common strategy known as "patent layering" or, less charitably, "evergreening."

Imbruvica patent rights are held across 2 entities: Pharmacyclics LLC, AbbVie Inc.. Multi-assignee portfolios usually reflect co-development partnerships, licensing splits between an originator and a marketing partner, or assignments made during corporate restructurings. Multi-party ownership can complicate generic entry — a challenger may need to clear patents from each holder separately, and settlements are harder to reach.

The Imbruvica portfolio scores 38/100 (Grade D, "weak") on the PatentCliff Strength index. The strongest signal is claims breadth (74/100), and the weakest is portfolio size (10/100). The four factors are weighted by how well they predict real-world resilience to generic challenge: portfolio size 30%, claims breadth 25%, time remaining 25%, and technology diversity 20%.

Looking at the 5 dated patents in the portfolio, the largest cluster (3 patents) falls in the "5–10 years (2032–2036)" bucket. That distribution matters because generic entry is gated by the latest unexpired blocking patent, not the earliest — even one late-expiring formulation patent can delay biosimilar launch by years if it survives a Paragraph IV challenge.

The 20-year patent term in the United States runs from the earliest non-provisional filing date, not the grant date. That means a patent granted in 2015 from a 2010 filing has only 15 years of life left at grant — a feature of US patent law that creates the layered "cliff" pattern visible in most branded drug portfolios. Patent Term Extension under 35 USC § 156 can add up to 5 years for time lost to FDA review, and pediatric exclusivity can add 6 months on top.